Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial fibrillation. The risk of bleeding was lower with dabigatran therapy; prevention of thromboembolic events was similar with the two strategies.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-10, Vol.377 (16), p.1513-1524
Hauptverfasser:	Cannon, Christopher P, Bhatt, Deepak L, Oldgren, Jonas, Lip, Gregory Y.H, Ellis, Stephen G, Kimura, Takeshi, Maeng, Michael, Merkely, Bela, Zeymer, Uwe, Gropper, Savion, Nordaby, Matias, Kleine, Eva, Harper, Ruth, Manassie, Jenny, Januzzi, James L, ten Berg, Jurrien M, Steg, P. Gabriel, Hohnloser, Stefan H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine - adverse effects Adenosine - analogs & derivatives Adenosine - therapeutic use Aged Anticoagulants Anticoagulants - adverse effects Anticoagulants - therapeutic use Antiplatelet therapy Aspirin Aspirin - therapeutic use Atrial Fibrillation - drug therapy Atrial Fibrillation - therapy Bleeding Cardiac arrhythmia Cardiology Cerebral infarction Clopidogrel Dabigatran - adverse effects Dabigatran - therapeutic use Drug dosages Drug therapy Drug Therapy, Combination - adverse effects Embolism Embolisms Female Fibrillation Geriatrics Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Incidence Male Middle Aged Myocardial infarction Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - therapeutic use Preventive medicine Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Risk Stroke Thromboembolism Thrombosis Ticagrelor Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use Warfarin Warfarin - adverse effects Warfarin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial fibrillation. The risk of bleeding was lower with dabigatran therapy; prevention of thromboembolic events was similar with the two strategies.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1708454